fluphenazine depot has been researched along with Recrudescence in 38 studies
fluphenazine decanoate : The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-three volunteer patients with recent-onset schizophrenia who had been clinically stabilized on a maintenance regimen of fluphenazine decanoate for a mean of 16." | 5.09 | Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. ( Aravagiri, M; Bartzokis, G; Fogelson, DL; Gitlin, M; Mintz, J; Nuechterlein, K; Subotnik, KL; Ventura, J, 2001) |
| "This study examined substance use among a group of 37 schizophrenia patients participating in a year-long fluphenazine decanoate (FD; Prolixin) dosage reduction study (Inderbitzin et al." | 5.08 | Substance use: a powerful predictor of relapse in schizophrenia. ( Inderbitzin, LB; Kasckow, JW; Scheller-Gilkey, G; Swofford, CD, 1996) |
| "This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia." | 5.07 | A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994) |
| "In an attempt to begin to establish minimum effective dosage requirements for the maintenance treatment of schizophrenia, we undertook a double-blind comparison of low-dose fluphenazine decanoate (1." | 5.05 | Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. ( Kane, JM; Ramos-Lorenzi, J; Reardon, G; Rifkin, A; Sarantakos, S; Schiebel, D; Woerner, M, 1983) |
| " The evidence available from prospective controlled trials suggests that substantial dosage reduction is feasible for a subgroup of outpatient schizophrenics and that the incidence of abnormal involuntary movements might be reduced by such a strategy." | 2.65 | Low dose medication strategies in the maintenance treatment of schizophrenia. ( Kane, JM, 1983) |
| " In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance." | 2.38 | Dose response of prophylactic antipsychotics. ( Brauzer, B; Casey, DE; Davis, JM; Gierl, B; Hassan, M; Kane, JM; Marder, SR; Schooler, N, 1993) |
| "This high rate of relapse is viewed as indicating the need for continued medication in most chronic schizophrenic patients." | 1.26 | Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. ( Aderounmu, AF; Odejide, OA, 1982) |
| "281 newly admitted female schizophrenic patients were treated with high dosage fluphenazine decanoate intramuscularly, starting with 250 mg per injection together with antiparkinsonian and antidepressant drugs." | 1.26 | Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate. ( Nagy, C; Steiner, S, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (68.42) | 18.7374 |
| 1990's | 11 (28.95) | 18.2507 |
| 2000's | 1 (2.63) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, DA | 1 |
| Pasterski, G | 1 |
| Ludlow, JM | 1 |
| Street, K | 1 |
| Taylor, RD | 1 |
| Müller, P | 1 |
| Kane, JM | 7 |
| Hogarty, GE | 1 |
| Leff, J | 1 |
| Kuipers, L | 1 |
| Berkowitz, R | 1 |
| Eberlein-Fries, R | 1 |
| Sturgeon, D | 1 |
| Rifkin, A | 4 |
| Quitkin, F | 1 |
| Nayak, D | 2 |
| Ramos-Lorenzi, J | 2 |
| Woerner, M | 2 |
| Reardon, G | 2 |
| Sarantakos, S | 1 |
| Schiebel, D | 1 |
| Wistedt, B | 2 |
| Ranta, J | 1 |
| Marder, SR | 3 |
| Van Putten, T | 2 |
| Mintz, J | 4 |
| McKenzie, J | 1 |
| Lebell, M | 1 |
| Faltico, G | 1 |
| May, PR | 1 |
| Marriott, P | 1 |
| Pansa, M | 1 |
| Hiep, A | 1 |
| Palmstierna, T | 1 |
| Mattes, JA | 1 |
| Odejide, OA | 1 |
| Aderounmu, AF | 1 |
| Steiner, S | 2 |
| Nagy, C | 1 |
| Siris, SG | 3 |
| Bermanzohn, PC | 1 |
| Mason, SE | 1 |
| Shuwall, MA | 1 |
| Inderbitzin, LB | 2 |
| Lewine, RR | 1 |
| Scheller-Gilkey, G | 2 |
| Swofford, CD | 2 |
| Egan, GJ | 1 |
| Gloersen, BA | 1 |
| Vidanagama, BP | 1 |
| Waternaux, C | 1 |
| Davis, JM | 1 |
| Brauzer, B | 1 |
| Gierl, B | 1 |
| Schooler, N | 1 |
| Casey, DE | 1 |
| Hassan, M | 1 |
| Hawton, K | 1 |
| Ware, C | 1 |
| Mistry, H | 1 |
| Hewitt, J | 1 |
| Kingsbury, S | 1 |
| Roberts, D | 1 |
| Weitzel, H | 1 |
| Kasckow, JW | 1 |
| Schooler, NR | 1 |
| Keith, SJ | 1 |
| Severe, JB | 1 |
| Matthews, SM | 1 |
| Bellack, AS | 1 |
| Glick, ID | 1 |
| Hargreaves, WA | 1 |
| Ninan, PT | 1 |
| Frances, A | 1 |
| Jacobs, M | 1 |
| Lieberman, JA | 1 |
| Mance, R | 1 |
| Simpson, GM | 1 |
| Woerner, MG | 1 |
| Heresco-Levy, U | 1 |
| Greenberg, D | 1 |
| Lerer, B | 1 |
| Javitt, DC | 1 |
| Brown, WA | 1 |
| Gitlin, M | 3 |
| Nuechterlein, K | 1 |
| Subotnik, KL | 1 |
| Ventura, J | 2 |
| Fogelson, DL | 1 |
| Bartzokis, G | 1 |
| Aravagiri, M | 1 |
| Soni, SD | 1 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Krska, J | 1 |
| Nuechterlein, KH | 2 |
| Dawson, ME | 2 |
| Goldstein, MJ | 1 |
| Snyder, KS | 2 |
| Yee, CM | 1 |
| Gómez Vegas, A | 1 |
| Silmi Moyano, A | 1 |
| Blázquez Izquierdo, J | 1 |
| Corral Rosillo, J | 1 |
| Delgado Martín, JA | 1 |
| Gómez Ruiz, JJ | 1 |
| Prieto Chaparro, L | 1 |
| Salinas Casado, J | 1 |
| Ushakov, IuV | 1 |
| Kravchenko, NE | 1 |
| Hirsch, SR | 2 |
| Jolley, AG | 1 |
| Borenstein, M | 2 |
| Boza, RA | 1 |
| Milanes, F | 1 |
| Starkey, T | 1 |
| Slater, V | 1 |
| Dominguez, F | 1 |
| Asarnow, RF | 1 |
| Zimmerman, KE | 1 |
| Strahan, A | 2 |
| Kreisman, D | 1 |
| Blumenthal, R | 1 |
| Kane, J | 1 |
| Jayaram, G | 1 |
| Coyle, J | 1 |
| Tune, L | 1 |
| Rappe, S | 1 |
| Fogelson, D | 1 |
| Curson, DA | 1 |
| Barnes, TR | 1 |
| Bamber, RW | 1 |
| Platt, SD | 1 |
| Duffy, JC | 1 |
| Reardon, GT | 1 |
| Doddi, SR | 1 |
| Hall, KS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics[NCT03376763] | Phase 4 | 201 participants (Actual) | Interventional | 2017-11-21 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
2 reviews available for fluphenazine depot and Recrudescence
| Article | Year |
|---|---|
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Sche | 1984 |
Dose response of prophylactic antipsychotics.
Topics: Administration, Oral; Aftercare; Antipsychotic Agents; Combined Modality Therapy; Delayed-Action Pre | 1993 |
21 trials available for fluphenazine depot and Recrudescence
| Article | Year |
|---|---|
Low dose medication strategies in the maintenance treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Re | 1983 |
Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Topics: Antipsychotic Agents; Attitude to Health; Behavior Therapy; Clinical Trials as Topic; Family; Family | 1984 |
Psychosocial relevance and benefit of neuroleptic maintenance: experience in the United Kingdom.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Attitude to Health; Clinical Trials as Topic; Delayed | 1984 |
Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
Topics: Adult; Aftercare; Double-Blind Method; Female; Fluphenazine; Humans; Male; Psychiatric Status Rating | 1982 |
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1983 |
Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Depression; Double-Blind Method; Flupenthixo | 1983 |
The use of depot neuroleptics: clinical experience in the United States.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Sche | 1984 |
Costs and benefits of two doses of fluphenazine.
Topics: Adult; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sch | 1984 |
Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Flupenthixol; Fluphenazine; Humans; Male; P | 1983 |
Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial.
Topics: Adult; Antipsychotic Agents; Benztropine; Delayed-Action Preparations; Depressive Disorder; Double-B | 1994 |
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Topics: Adult; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Double | 1994 |
Paracetamol self-poisoning. Characteristics, prevention and harm reduction.
Topics: Acetaminophen; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparation | 1996 |
Substance use: a powerful predictor of relapse in schizophrenia.
Topics: Adult; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, | 1996 |
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Topics: Adolescent; Adult; Ambulatory Care; Combined Modality Therapy; Delayed-Action Preparations; Dose-Res | 1997 |
Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluph | 1997 |
Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cross-Over Studies; Double-Blind Method; Fluphenazine; Foll | 2001 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.
Topics: Adolescent; Adult; Attitude to Health; Autonomic Nervous System; Double-Blind Method; Female; Fluphe | 1992 |
The dysphoric syndrome in schizophrenia and its implications for relapse.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Fluphenazine; Fol | 1989 |
Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluphenazine; Humans; Male; Middl | 1988 |
Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view.
Topics: Adolescent; Adult; Attitude; Dose-Response Relationship, Drug; Family; Female; Fluphenazine; Humans; | 1988 |
Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Fluphenazine; Follow-Up Studies; Humans; Recu | 1985 |
16 other studies available for fluphenazine depot and Recrudescence
| Article | Year |
|---|---|
The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Flupenthixol; Fl | 1983 |
[What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
Topics: Ambulatory Care; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Administration Sch | 1983 |
Intervals between long acting neuroleptics: outcome and re-admission variables.
Topics: Age Factors; Chronic Disease; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Patient Readmis | 1984 |
Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives.
Topics: Adolescent; Adult; Double-Blind Method; Drug Therapy, Combination; Fluphenazine; Humans; Lithium; Mi | 1984 |
Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Topics: Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Fluphenazine; Humans; Psychiatric | 1982 |
[Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
Topics: Adolescent; Adult; Aged; Child; Drug Administration Schedule; Fluphenazine; Follow-Up Studies; Human | 1980 |
Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
Topics: Age Factors; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Humans; Recurrence; | 1981 |
Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
Topics: Administration, Oral; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Dyskinesia, | 1992 |
[Priapism secondary to phenothiazines].
Topics: Adult; Delayed-Action Preparations; Drainage; Fluphenazine; Humans; Male; Middle Aged; Priapism; Rec | 1991 |
[Clinico-economical aspects of long-term therapy with moditen-depot].
Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Tolerance | 1990 |
Compliance in the long-term treatment of schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Humans; Patient Compliance; Recurrence; Sc | 1985 |
Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
Topics: Adult; Antipsychotic Agents; Female; Fluphenazine; Follow-Up Studies; Humans; Male; Middle Aged; Pat | 1988 |
Continuation and maintenance treatment trials of adjunctive imipramine therapy in patients with postpsychotic depression.
Topics: Benztropine; Depressive Disorder; Drug Therapy, Combination; Fluphenazine; Humans; Imipramine; Psych | 1988 |
Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Female; Fluphenazine; Humans; Injections, | 1986 |
Expressed emotion, fixed-dose fluphenazine decanoate maintenance, and relapse in recent-onset schizophrenia.
Topics: Adult; Emotions; Family; Female; Fluphenazine; Humans; Male; Recurrence; Schizophrenia; Schizophreni | 1986 |
Stability of the postpsychotic depression syndrome.
Topics: Adult; Depressive Disorder; Female; Fluphenazine; Humans; Male; Middle Aged; Outcome and Process Ass | 1986 |